Skip to main content

Table 5 Univariate analysis of prognostic factors for patients with locoregionally advanced NPC

From: Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

Variate 5-year survival rate (%)
OS P LRRFS P DMFS P DFS P
Gender   0.173   0.587   0.077   0.224
 Male 75.8   87.1   75.3   65.9  
 Female 88.0   83.3   85.8   74.0  
Age (years)   0.002   0.489   0.025   0.007
 <50 82.8   87.0   81.5   73.1  
 ≥50 68.6   84.6   68.4   55.6  
WHO histology   0.362   0.564   0.526   0.549
 Type II 87.1   90.3   83.3   74.5  
 Type III 77.5   85.8   76.9   66.9  
T stage   0.213   0.070   0.773   0.299
 T1–2 84.4   96.4   81.3   78.1  
 T3–4 77.4   84.6   76.9   66.0  
N stage   0.934   0.475   0.414   0.994
 N0–1 80.8   85.2   79.4   67.2  
 N2–3 75.1   87.8   74.9   68.2  
Overall stage   <0.001   0.518   0.001   0.004
 III 85.6   87.7   84.9   74.7  
 IV 66.5   83.5   65.3   56.2  
Treatment   0.599   0.515   0.456   0.517
 NAC + IMRT 78.0   87.9   79.0   69.8  
 CCRT + AC 78.7   84.8   76.2   65.6